Amarin Reports Potential Legacy Effect of Icosapent Ethyl in New REDUCE-IT Analysis
Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...
EVANSTON, Ill., June 2, 2026 Researchers at Endeavor Health have developed a groundbreaking genetic screening tool designed to provide...
Boulder, Colorado — February 10, 2026: The American Journal of Preventive Cardiology (AJPC) has published a landmark multinational study...
Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation...
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
